Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre

HPB

Volumn 14, Issue 3, 2012, Pages 162-170

  Eltawil, Karim M ^a   Berry, Robert ^b   Abdolell, Mohamed ^a   Molinari, Michele ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

body mass index; hepatocellular carcinoma; MELD; multivariate Cox regression survival analysis; predictors; survival; TACE; transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; IODINATED POPPYSEED OIL; LAMIVUDINE; POLYVINYL ALCOHOL;

ADULT; AGED; ARTICLE; BODY MASS; CANADA; CANCER STAGING; CASE REPORT; CATHETER; CHEMOEMBOLIZATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; HEPATIC ARTERY; HEPATITIS B; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER CELL CARCINOMA; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; REGRESSION ANALYSIS; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84857041582     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2011.00420.x     Document Type: Article

References (36)

1. Kamangar F, Dores GM, Anderson WF,. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150. (Pubitemid 46655601)
2. Parkin DM, Bray F, Ferlay J, Pisani P,. (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156. (Pubitemid 32911406)
3. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Registry. 2007. [Accessed 3 October 2011.
4. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ,. (2000) Radiofrequency ablation of 231 unresectable hepatic tumours: indications, limitations, and complications. Ann Surg Oncol 7: 593-600.
5. Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, et al,. (2009) Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumour necrosis. Clin Transplant 23 (Suppl. 21): 61-67.
6. Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, et al,. (2011) Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatobiliary Pancreat Dis Int 10: 143-150.
7. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS,. (2010) Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB (Oxford) 12: 174-180.
8. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al,. (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20 (Suppl. 7): 1-6.
9. Lau WY, Lai EC,. (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7: 237-257. (Pubitemid 351895383)
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al,. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
11. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al,. (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359: 1734-1739. (Pubitemid 34607087)
12. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al,. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171. (Pubitemid 34454013)
13. Pons F, Varela M, Llovet JM,. (2005) Staging systems in hepatocellular carcinoma. HPB (Oxford) 7: 35-41. (Pubitemid 40425755)
14. Child CG, Zuidema GD,. (1964) Experimental surgery of the portal vein, hepatic artery and hepatic veins. Major Probl Clin Surg 1: 189-224.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al,. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
16. Bruix J, Sherman M,. (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
17. Pang YY,. (2000) The Brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford) 2: 333-339.
18. American Joint Committee on Cancer. (2010) AJCC Cancer Staging Handbook, 7th edn. New York, NY: Springer-Verlag.
19. Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, et al,. (2006) Transarterial chemoembolization for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) 18: 684-692. (Pubitemid 44464049)
20. Farinati F, De Maria N, Marafin C, Herszenyi L, Del Prato S, Rinaldi M, et al,. (1996) Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side-effects after transcatheter arterial chemoembolization. Dig Dis Sci 41: 2332-2339.
21. Bosch FX, Ribes J, Borras J,. (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19: 271-285. (Pubitemid 29488770)
22. Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y, Harada M,. (1981) Arterial chemoembolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects. JAMA 245: 1123-1127. (Pubitemid 11095958)
23. Llovet JM, Bruix J,. (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442. (Pubitemid 36152543)
24. Bruix J, Sherman M,. (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
25. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al,. (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469. (Pubitemid 44142456)
26. Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, et al,. (2008) Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol 9: 534-540.
27. Berger DH, Carrasco CH, Hohn DC, Curley SA,. (1995) Hepatic artery chemoembolization or embolization for primary and metastatic liver tumours: post-treatment management and complications. J Surg Oncol 60: 116-121.
28. Okuda K, Obata H, Nakajima Y, Ohtsuki T, Okazaki N, Ohnishi K,. (1984) Prognosis of primary hepatocellular carcinoma. Hepatology 4 (Suppl.): 3-6.
29. Lopez RR Jr, Pan SH, Hoffman AL, Ramirez C, Rojter SE, Ramos H, et al,. (2002) Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs. focal hepatocellular carcinoma. Arch Surg 137: 653-657; discussion 657-658.
30. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP,. (1999) Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 28: 334-340. (Pubitemid 29246409)
31. Sarasin FP, Giostra E, Hadengue A,. (1996) Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis. Am J Med 101: 422-434. (Pubitemid 26392861)
32. Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, et al,. (2010) Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol 25: 1426-1434.
33. Qian MY, Yuwei JR, Angus P, Schelleman T, Johnson L, Gow P,. (2010) Efficacy and cost of a hepatocellular carcinoma screening programme at an Australian teaching hospital. J Gastroenterol Hepatol 25: 951-956.
34. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al,. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699. (Pubitemid 26079803)
35. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al,. (2010) Prospective randomized study of doxorubicin-eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33: 41-52.
36. Sheth M, Riggs M, Patel T,. (2002) Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2: 2.